XOLAIR offers treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria in appropriate patients... Read more
XOLAIR offers treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria in appropriate patients... Read more
CEO
Add
Add Founded Year
PrivateIndependent Company
News
Mar 26, 2025
StreetInsider
Press Release: Xolair : UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair (omalizumab)
Mar 20, 2025
MedCity News
Xolair: Transforming Allergy Care: The Power of Advanced Diagnostics in Improving Patient Outcomes
Mar 09, 2025
Medthority
Xolair: FDA Approves Omlyclo as First Biosimilar to Reference Xolair
Mar 04, 2025
Pharmabiz
Xolair: Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies
Mar 03, 2025
PharmaLive
Xolair: First head-to-head study cements Roche's Xolair as food allergy leader
Jul 25, 2024
Business Wire
Press Release: Xolair : Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR (omalizumab)
Jul 01, 2024
MarketScreener
Xolair: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Mar 12, 2024
Pharmabiz
Xolair: Celltrion USA submits BLA to US FDA for CTP39, an interchangeable biosimilar candidate of Xolair
Feb 26, 2024
Reuters
Xolair: Roche's Xolair reduces reactions to severe food allergies in study
Feb 25, 2024
MarketScreener
Xolair: New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
